Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 15, Issue 4, 1996, Pages 291-296

  Gonzalez Barca E ^a   Fernandez Sevilla A ^a   Carratala J ^a   Granena A ^a   Gudiol, F ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTEREMIA; CANCER PATIENT; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INTRAVASCULAR CATHETER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STAPHYLOCOCCUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; INCIDENCE; LEUKEMIA; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PROSPECTIVE STUDIES; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCAL INFECTIONS; TIME FACTORS;

EID: 0029953177     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01695660     Document Type: Article

References (26)

1. Pizzo PA, Thaler M, Hathorn J: New beta-lactam antibiotics in granulocytopenic patients. American Journal of Medicine 1985, 79, Supplement 2: 75-82.
2. Bodey GP, Buckley M, Sathe YS, Freireich EJ: Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine 1966, 64: 328-340.
3. Singer C, Kaplan MH, Armstrong D: Bacteremia and fungemia complicating neoplastic disease. American Journal of Medicine 1977, 62: 731-742.
4. Whimbey E, Kiehn TE, Brannon P, Blevins A, Armstrong D: Bacteremia and fungemia in patients with neoplastic disease. American Journal of Medicine 1987, 82: 723-730.
5. The EORTC International Antimicrobial Therapy Project Group: Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. Journal of Infectious Diseases 1978, 137: 14-29.
6. The EORTC International Antimicrobial Therapy Cooperative Group: Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytope-nia. New England Journal of Medicine 1987, 317: 1692-1698.
7. The EORTC International Antimicrobial Therapy Cooperative Group: Gram-positive bacteremia in granulocytopenic cancer patients. European Journal of Cancer 1990, 26: 569-574.
8. Cometta A, Zinner S, Bock R, Calandra T, Gaya H, Klastersky J, Langenaeken J, Paesmans M, Viscoli C, Glauser MP, and the International Antimicrobial Therapy Cooperative Group of the EORTC: Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrobial Agents and Chemotherapy 1995, 39: 445-452.
9. Centers for Disease Control: National nosocomial infections study site definitions manual. Centers for Disease Control, Atlanta, GA, 1972, p. 82-84.
10. Isenberg HD, Baron EJ, D'Amato RF, Johnson RC, Murray PR, Rodgers FG, von Graevenitz A: Recommendations for the isolation of bacteria from clinical specimens. In: Balows A, Hausler WJ, Herrmann KL, Isenberg HD, Shadomy HJ (ed): Manual of clinical microbiology. American Society for Microbiology, Washington DC, 1991, p. 216-221.
11. International Antimicrobial Therapy Cooperative Group of the EORTC: Efficacy and toxicity of single daily dose of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infections in patients with cancer and granulocytopenia. Annals of Internal Medicine 1993, 119: 584-593.
12. Winston DJ, Dudnick DV, Chapin M, Ho WG, Gale RP, Martin WJ: Coagulase-negative stapnylococcal bacteremia in patients receiving immunosuppressive therapy. Archives of Internal Medicine, 143: 32-36.
13. Wade JC, Schimpff SC, Newman KA, Wiernik PH: Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Annals of Internal Medicine 1982, 97: 507-508.
14. Bochud PY, Eggiman P, Calandra T, Van Melle B, Saghafi L, Francioli P: Bacteremia due to viridans streptococci in neutropenic patients with cancer: clinical spectrum and risk factors. Clinical Infectious Diseases 1994, 18: 25-31.
15. Elting LS, Bodey GP, Keefe BH: Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clinical Infectious Diseases 1992, 14: 1201-1207.
16. Carratalá J, Alcaide F, Fernández-Sevilla A, Corbella X, Liñares J, Gudiol F: Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clinical Infectious Diseases 1995, 20: 1169-1173.
17. McWhinney PHM, Patel S, Whiley RA, Hardie JM, Gillespie SH, Kibbler CC: Activities of potential therapeutic and prophylactic antibiotics against blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin. Antimicrobial Agents and Chemotherapy 1993, 37: 2493-2495.
18. Winston DJ, Ho WG, Nako SL, Gale PR, Champlin RE: Norfloxacin versus vancomycin-polymixin for prevention of infections in granulocytopenic patients. American Journal of Medicine 1986, 80: 884-890.
19. Bow EJ, Rayner E, Louie TJ: Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade off for reduced gram negative sepsis. American Journal of Medicine 1988, 84: 847-854.
20. Karp JE, Merz WG, Hendricksen C, Laughon B, Redden T, Bamberger BJ, Barlett JC, Saral R, Burke PJ: Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 1987, 106: 1-7.
21. Carratalá J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F: Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clinical Infectious Diseases 1995, 20: 557-560.
22. Kern MV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R: Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrobial Agents and Chemotherapy 1994, 38: 681-687.
23. Cometta A, Calandra T, Bille J, Glauser MP: Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. New England Journal of Medicine 1994, 330: 1240-1241.
24. Gordon B, Spadinger A, Hodges E, Ruby E, Stanley R, Coccia P: Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation. Journal of Clinical Oncology 1994, 12: 1917-1922.
25. Brown AT, Sims RE, Raybould TP, Lillich TT, Henslee A, Ferreti GA: Oral gram-negative bacilli in bone marrow transplant patients given chlorexidine rinses. Journal of Dental Research 1989, 68: 1199-1204.
26. Schartz C, Henrickson KJ, Roghmann K, Powell K: Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms. Journal of Clinical Oncology 1990, 8: 1591-1597.